In brief: Rockeby, C3, Heartware
Friday, 04 March, 2005
Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.
Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.
HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
